Page 11234..1020..»

Category : Nanomedicine

Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead…

SALT LAKE CITY, Jan. 21, 2020 /PRNewswire/ --Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announcedits Australian subsidiary had completed enrollment and dosing of the first participant in the Phase 2 RESCUE-ALS study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The RESCUE-ALS study is substantially funded by FightMND.

"The objective of the randomized, double-blind RESCUE-ALS study is to demonstrate that improvements in brain bioenergetic cellular support in early symptomatic ALS patients treated with CNM-Au8 will help preserve motor neurons survival and function. The primary endpoint is the mean change in the average difference between active treatment and placebo from baseline through week 36 for the Motor Unit Number Index (MUNIX) score, which quantitatively reflects the loss of motor neurons in ALSthe primary cause of clinical progression in ALS," said Robert Glanzman, MD, FAAN, Clene's Chief Medical Officer.

"We are excited to advance CNM-Au8 clinically into this Phase 2 study for ALS patients," said Rob Etherington, President and CEO of Clene. "As neurodegenerative diseases such as ALS have very few treatment options, this study will prove whether CNM-Au8 may be an effective disease-modifying treatment for people with ALS."

"We are very excited to partner with Clene on the Phase 2 study in ALS, RESCUE-ALS," said Professor Steve Vucic, Director of Neurophysiology, Department of Neurology, at Sydney Medical School, Westmead Hospital. "CNM-Au8 offers an innovative approach of potentially treating neurodegenerative diseases, such as ALS, for which there are no effective treatments at present. We are hopeful that CNM-Au8 will be an effective therapy in the future and this trial will go a long way in addressing this question."

About RESCUE-ALS

RESCUE-ALS is Phase 2 multi-center randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic ALS (within 24-months of screening or 12-months from diagnosis) and with a clinically probable or possible or definite ALS diagnosis. Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 30 mg or placebo in addition to their current standard of care. Participants will receive their randomized oral treatment daily over 36 consecutive weeks during the Treatment Period. The treatment is taken by mouth once daily first thing every morning. The objective of this study is to assess bioenergetic catalysis with CNM-Au8 to slow disease progression in patients with ALS.

About CNM-Au8

CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted nanocrystalline gold (Au) that acts catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteersand both remyelination and neuroprotection effects in multiple preclinical models. Preclinical data presented at scientific congresses demonstrated that treatment with CNM-Au8 in neuronal cultures improved survival of neurons, protected neurite networks, decreased intracellular levels of reactive oxygen species, and improved mitochondrial capacity in response to cellular stress, induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in a rodent models of ALS, multiple sclerosis, and Parkinson's disease versus vehicle (placebo). CNM-Au8 has received regulatory approval to proceed to clinical studies for the treatment of remyelination failure in patients with multiple sclerosis and neuroprotection in patients with amyotrophic lateral sclerosis(ALS) and Parkinson's disease.

About Amyotrophic Lateral Sclerosis (ALS)

ALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About Clene

Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company, focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

About FightMND

FightMND is a not-for-profit registered charity, founded in 2014. It was established to raise the awareness of Motor Neurone Disease (MND) in Australia, to increase funding for research to find an effective treatment and cure and to provide care equipment for MND patients. We have a clear objective to a have a world free from MND.

FightMND is Australia's largest independent MND foundation focused on funding large- scale, collaborative research and clinical trials. The generous donations contributed by everyday Australians, right across the country, has enabled FightMND to raise and commit millions to cure and care initiatives.

Investor ContactKaitlyn BroscoThe Ruth Group646-536-7032 kbrosco@theruthgroup.com

Media Contact Kirsten ThomasThe Ruth Group508-280-6592 kthomas@theruthgroup.com

View original content:http://www.prnewswire.com/news-releases/clene-nanomedicine-announces-first-patient-dosed-in-the-rescue-als-clinical-trial-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-with-lead-nanocatalytic-therapeutic-cnm-au8-300989992.html

SOURCE Clene Nanomedicine, Inc.

Original post:
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead...

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine Market: 2020 Global Industry Growth Prospects and Insights on Future Scenario | Company Profiles Combimatrix, Ablynx, Abraxis Bioscience,…

The Global Nanomedicine Market research report includes various topics like total industry size, key drivers, challenges, growth opportunities, share, growth, demand, outlook etc. it covers key market updates, the impact of regulations and technological updates.

The report addresses the need to stay updated in this competitive industry conditions and this provides and comprehensive data for making strategies and decision so as to stimulate the market growth and profitability.

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points within the industrys value chain.

No. of Pages: 124

Inquire more or share questions if any before the purchase on Nanomedicine Industry report @https://www.orianresearch.com/enquiry-before-buying/627186

Report Covers Market Segment by Manufacturers: Combimatrix Ablynx Abraxis Bioscience Celgene Mallinckrodt Arrowhead Research GE Healthcare Merck

Market Segment by Type, covers: Quantum dots Nanoparticles Nanoshells Nanotubes Nanodevices

Market Segment by Applications, can be divided into: Segmentation encompasses oncology Infectious diseases Cardiology Orthopedics Others

Order Copy of this Report @https://www.orianresearch.com/checkout/627186

There are 15 Chapters to deeply display the global Nanomedicine market.Chapter 1: Describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force.

About UsOrian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Here is the original post:
Nanomedicine Market: 2020 Global Industry Growth Prospects and Insights on Future Scenario | Company Profiles Combimatrix, Ablynx, Abraxis Bioscience,...

Recommendation and review posted by Alexandra Lee Anderson

Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN – Dove Medical Press

Hossein Derakhshankhah, 1, 2,* Samira Jafari, 1, 2,* Sajad Sarvari, 3 Ebrahim Barzegari, 4 Faezeh Moakedi, 5 Milad Ghorbani, 6 Behrang Shiri Varnamkhasti, 1 Mehdi Jaymand, 7 Zhila Izadi, 1, 8 Lobat Tayebi 9

1Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Zistmavad Pharmed Co., Tehran, Iran; 3Department of Pharmaceutical and Pharmacological Science, School of Medicine, West Virginia University, Morgantown, WV, USA; 4Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 5Department of Biochemistry and Molecular Biology, School of Medicine, West Virginia University, Morgantown, WV, USA; 6Department of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran; 7Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 8Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; 9Marquette University School of Dentistry, Milwaukee, WI 53201, USA

*These authors contributed equally to this work

Correspondence: Zhila Izadi; Lobat Tayebi Email izadi_zh@razi.tums.ac.ir; lobat.tayebi@marquette.edu

Abstract: The advent of porous materials, in particular zeolitic nanoparticles, has opened up unprecedented putative research avenues in nanomedicine. Zeolites with intracrystal mesopores are low framework density aluminosilicates possessing a regular porous structure along with intricate channels. Their unique physiochemical as well as physiological parameters necessitate a comprehensive overview on their classifications, fabrication platforms, cellular/macromolecular interactions, and eventually their prospective biomedical applications through illustrating the challenges and opportunities in different integrative medical and pharmaceutical fields. More particularly, an update on recent advances in zeolite-accommodated drug delivery and the prevalent challenges regarding these molecular sieves is to be presented. In conclusion, strategies to accelerate the translation of these porous materials from bench to bedside along with common overlooked physiological and pharmacological factors of zeolite nanoparticles are discussed and debated. Furthermore, for zeolite nanoparticles, it is a matter of crucial importance, in terms of biosafety and nanotoxicology, to appreciate the zeolite-bio interface once the zeolite nanoparticles are exposed to the bio-macromolecules in biological media. We specifically shed light on interactions of zeolite nanoparticles with fibrinogen and amyloid beta which had been comprehensively investigated in our recent reports. Given the significance of zeolite nanoparticles interactions with serum or interstitial proteins conferring them new biological identity, the preliminary approaches for deeper understanding of administration, distribution, metabolism and excretion of zeolite nanoparticles are elucidated.

Keywords: zeolite, mesoporous, nanostructure, biosafety, biomedical applications

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the article here:
Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN - Dove Medical Press

Recommendation and review posted by Alexandra Lee Anderson

Complete Overview of Cancer Nanomedicine Market to Witness High Rate of Growth in Forthcoming Years – Fusion Science Academy

A recent market study published by XploreMR titled Endoscopy Fluid Management System Market: Global Industry Analysis 20132017 & Opportunity Assessment 20182028 comprises a comprehensive assessment of the most important market dynamics. Growth prospects of the endoscopy fluid management system market are obtained with maximum precision through thorough research on historic as well as current growth parameters. The report features unique and salient factors that are likely to make a huge impact on the development of the endoscopy fluid management system market during the forecast period. A better understanding of these factors can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the endoscopy fluid management system market in the coming years. The report provides detailed information about the current and future growth prospects of the endoscopy fluid management system market in the most comprehensive way for the better understanding of readers.

Chapter 1 Executive Summary

The report commences with an executive summary of the endoscopy fluid management system market report, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the endoscopy fluid management system market.

Chapter 2 Market Introduction

Readers can find detailed taxonomy and definitions in this chapter to understand basic information regarding the endoscopy fluid management system market dynamics, supply chain, list of key distributors and suppliers and list of key market participants.

Chapter 3 Market Overview

Readers can find a detailed opportunity analysis on Endoscopy Fluid Management System Market

Chapter 4 Market Overview

Tracking the market scenario, with key inferences drawn from historical data, current trends, and future prospects. This section provides the Macro-Economic Factors for the market

Chapter 5 Market Background

Readers can find various macro-economic factors associated with the growth of the market. This chapter highlights the key market dynamics, which include the drivers, restraints and trends

Chapter 6 Global Economic Outlook

This section shows the Gross Domestic Product by Region & Country from 2006 2021

Chapter 7 Key Inclusions

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/3047

This section of the report includes regulation and reimbursement scenario associated with the market

Chapter 8 North America Endoscopy Fluid Management System Market Analysis 20132017 & Opportunity Assessment 20182028

This chapter includes a detailed analysis of the anticipated growth in the North America endoscopy fluid management system market along with a country-wise assessment for countries in the region, including the U.S. and Canada. Readers can also find information pertaining to the regional trends and regulations prevailing in the North America endoscopy fluid management system market and regional market growth classified on the basis of product type, modality and end user.

Chapter 9 Latin America Endoscopy Fluid Management System Market Analysis 20132017 & Opportunity Assessment 20182028

Readers can find detailed information regarding factors such as pricing analysis and regional trends that are impacting the growth of the Latin America endoscopy fluid management system market. This chapter also includes the growth prospects of the endoscopy fluid management system market in leading LATAM countries such as Brazil, Mexico and rest of the Latin America region.

Chapter 10 Europe Endoscopy Fluid Management System Market Analysis 20132017 & Opportunity Assessment 20182028

Important growth prospects of the endoscopy fluid management system market, on the basis of product type, modality and end user in several European countries such as Germany, the U.K., France, Italy, Spain, Russia, Poland & the rest of Europe have been included in this chapter.

Chapter 11 Asia Pacific Endoscopy Fluid Management System Market Analysis 20132017 & Opportunity Assessment 20182028

China, India, Australia and Japan, being the leading countries in the APEJ region, are the prime subject of assessment in this chapter to obtain the growth prospects of the APEJ endoscopy fluid management system market during the forecast period.

Chapter 12 MEA Endoscopy Fluid Management System Market Analysis 20132017 & Opportunity Assessment 20182028

This chapter provides information on how the endoscopy fluid management system market is expected to grow in major countries of the MEA region, such as Saudi Arabia, South Africa, & Egypt, during the period 20182028.

Chapter 13 Forecast Factors: Relevance and Impact

Forecast factors for the estimation of the entire concerned market are also present in this section.

Chapter 14 Forecast Assumptions

Taken assumptions set for the estimation of the entire concerned market are present in this section.

Request Report Methodology at https://www.xploremr.com/connectus/request-methodology/3047

Chapter 15 Market Structure Analysis

This chapter includes the market structure by tier of companies for the electrophysiology ablation market. This chapter also includes the company share analysis for various key players in the market.

Chapter 16 Competition Landscape

In this chapter, readers can find a comprehensive list of the leading stakeholders present in the endoscopy fluid management system market along with detailed information about each company, including company overview, revenue shares, strategic overview and recent company developments. Market players featured in the report include Stryker, Olympus Corporation, KARL STORZ SE & Co. KG, Smith & Nephew Plc., Hologic Inc., Richard Wolf GmbH, B. Braun Medical Inc., Cantel Medical Corporation and Medtronic & DePuy Synthes (Johnson & Johnson Services, Inc.).

Chapter 17 Global Endoscopy Fluid Management System Market Analysis (20132017) & Opportunity Assessment (20182028) by Region

This chapter explains how the endoscopy fluid management system market is expected to grow across various geographic regions such as North America, Latin America, Europe, Asia-Pacific Excluding Japan (APEJ), & the Middle East & Africa (MEA).

Chapter 18 Global Endoscopy Fluid Management System Market Analysis (20132017) & Opportunity Assessment (20182028) by Product Type

The endoscopy fluid management system market, on the basis of product type, has been segmented into laparoscopy fluid management systems, laparoscopy suction irrigation pumps, hysteroscopy fluid management systems and hysteroscopy pumps. In this chapter, readers can find information about the key trends and developments in the endoscopy fluid management system market and a market attractiveness analysis based on the product type.

Chapter 19 Global Endoscopy Fluid Management System Market Analysis (20132017) & Opportunity Assessment (20182028) by Modality

On the basis of the modality, the endoscopy fluid management system market has been segmented into floor standing & benchtop. In this chapter, readers can find information about the key trends and developments in the endoscopy fluid management system market and a market attractiveness analysis based on the modality.

Chapter 20 Global Endoscopy Fluid Management System Market Analysis (20132017) & Opportunity Assessment (20182028) by End User

On the basis of the end user, the endoscopy fluid management system market has been segmented into hospitals, ambulatory surgical centers, specialty clinics & diagnostic centers. In this chapter, readers can find information about the key trends and developments in the endoscopy fluid management system market and a market attractiveness analysis based on the end user.

Chapter 21 Global Endoscopy Fluid Management System Market Analysis (20132017) & Opportunity Assessment (20182028)

This chapter explains how the endoscopy fluid management system market is expected to grow across the period of 20182028.

Chapter 22 Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 23 Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions and important qualitative and quantitative information regarding the endoscopy fluid management system market.

Buy Full Report at https://www.xploremr.com/cart/3047/SL

We are a vibrant market research company which is focused on catering to more and more people day by day. Our research company is one of a few reliable market research report companies in todays date.

See original here:
Complete Overview of Cancer Nanomedicine Market to Witness High Rate of Growth in Forthcoming Years - Fusion Science Academy

Recommendation and review posted by Alexandra Lee Anderson

Most engineered nanoparticles enter tumours through cells not between them, U of T researchers find – News@UofT

University of Toronto researchers have discovered that an active rather than passive process dictates which nanoparticles enter solid tumours, upending decades of thinking in the field of cancer nanomedicine and pointing toward more effective nanotherapies.

The prevailing theory in cancer nanomedicine an approach that enables more targeted therapies than standard chemotherapy has been that nanoparticles mainly diffuse passively into tumours through tiny gaps between cells in the endothelium, which lines the inner wall of blood vessels that support tumour growth.

The researchers previously showed thatless than one per centof nanoparticle-based drugs typically reach their tumour targets. In the current study, they found that among nanoparticles that do penetrate tumours, more than 95 per cent pass through endothelial cells not between gaps among those cells.

Our work challenges long-held dogma in the field and suggests a completely new theory, saysAbdullah Syed, a co-lead author on the study and post-doctoral researcher in the lab ofWarren Chan, a professor at theInstitute of Biomaterials and Biomedical Engineeringand theDonnelly Centre for Cellular and Biomolecular Research.

We saw many nanoparticles enter the endothelial cells from blood vessels and exit into the tumour in various conditions. Endothelial cells appear to be crucial gatekeepers in the nanoparticle transport process.

The findings were recently published in thejournalNature Materials.

From left to right: U of T researchers Jessica Ngai, Shrey Sindhwani, Abdullah Syed and Benjamin Kingston (photo by Qin Dai)

Syed compares nanoparticles to people trying to get into popular restaurants on a busy night. Some restaurants dont require a reservation, while others have bouncers who check if patrons made reservations, he says. The bouncers are a lot more common than researchers thought, and most places only accept patrons with a reservation.

The researchers established that passive diffusion was not the mechanism of entry with multiple lines of evidence. They took over 400 images of tissue samples from animal modelsand saw few endothelial gaps relative to nanoparticles. They observed the same trend using 3D fluorescent imaging and live-animal imaging.

Similarly, they found few gaps between endothelial cells in samples from human cancer patients.

The group then devised an animal model that completely stopped the transportation of nanoparticles through endothelial cells. This allowed them to isolate the contribution of passive transport via gaps between endothelial cells, which proved to be miniscule.

The researchers posit several active mechanisms by which endothelial cells might transport nanoparticles into tumours, including binding mechanisms, intra-endothelial channels and as-yet undiscovered processes all of which they are investigating.

Meanwhile, the results have major implications for nanoparticle-based therapeutics.

These findings will change the way we think about delivering drugs to tumours using nanoparticles, saysShrey Sindhwani, also a co-lead author on the paper and an MD/PhD student in the Chan lab. A better understanding of the nanoparticle transport phenomenon will help researchers design more effective therapies.

The research included collaborators from U of Ts department of physics in the Faculty of Arts & Science, Cold Spring Harbor Laboratory In New York and the University of Ottawa. The study was funded by the Canada Research Chairs Program, Canadian Cancer Society, Natural Sciences and Engineering Research Council of Canadaand the Canadian Institutes of Health Research.

Continued here:
Most engineered nanoparticles enter tumours through cells not between them, U of T researchers find - News@UofT

Recommendation and review posted by Alexandra Lee Anderson

Healthcare IT Market trends research and projections – GroundAlerts.com

The consumerization in healthcare information technology has reached a tipping point, the impact of which has been felt across healthcare IT market. The need to ensure comfort and security for patients has brought about a major transformation in the medical sphere, leading to a path-breaking intersection of IT and healthcare. The deployment of IT has equipped the healthcare industry with nanomedicine, virtual healthcare, 3D printing, robot-assisted surgery, and more. These advancements, aided by the investments by the governments worldwide, have brought about a massive change in the healthcare IT industry outlook.

The global healthcare IT market has also gained traction on account of innumerable parameters, prominent among them being, the increasing geriatric populace and the changing consumer lifestyles. Indeed, these have led to a spate of diseases worldwide, consequently surging the demand for a highly sophisticated healthcare IT network in order to lower errors in administration processes and ensure efficient medical data and patient record management.

Request sample copy of this report @ http://decresearch.com/request-sample/detail/232

Consumer expectations have also changed in the last decade or so, leading to healthcare providers focusing on prioritizing efficient management of healthcare data. This has subsequently led to the implementation of innovative technologies in the medical ecosphere, augmenting the revenue graph of the global healthcare IT market. Indeed, estimates claim that healthcare IT industry is expected to exceed $441.8 billion by the year 2025.

While numerous IT solutions are deployed in the healthcare space, one of the most significant ones is that of electronic health records. Undeniably, healthcare IT industry has gained much via rapid adoption of the EHR technology by healthcare specialists in the U.S. and other economies. According to the National Electronic Health Records Survey, 2017, approximately 9 out of 10 office-based physicians had adopted any type of EHR, while certified EHRs were adopted by 4 out of 5 office-based physicians. Since 2008, the rate of EHR adoption has more than doubled from 42 percent to nearly 86 percent in 2017. The accelerated adoption of EHR will thus drive the growth graph of healthcare IT industry from electronic health records. As a matter of fact, estimates claim that EHR-based healthcare IT market size will cross $97.8 billion by 2025.

Request for discount @ http://decresearch.com/request-discount/232

Regionally speaking, it has been forecast that the United States will crop up as a prime growth avenue for the global healthcare IT industry, primarily driven by numerous investments in medical care infrastructure and government mandates. More than half a decade ago, The U.S. Department of Health and Human Services (HHS) had mandated the adoption of information technology by healthcare providers. A substantial growth has also been recorded in terms of investments by the U.S. government in healthcare IT since 2008.

A few years ago, the U.S. government had made an investment of about $20 billion through the HITECH (Health Information Technology for Economic and Clinical Health) Act, for setting up electronic health records. Aided by numerous government initiatives and the escalating need for an efficient healthcare management system, the U.S. healthcare IT industry is estimated to record substantial revenues by 2025.

Speaking of government initiatives, yet another regional ground touted to garner extensive proceeds in healthcare IT market is the United Kingdom. In December 2018, a new collaboration had been announced between the government and the life sciences industry, backed by a government fund worth 79 million, in order to study 5 million people and develop AI-centric diagnostic tests. Back in 2014, the UK government has also announced an investment of $5.4 billion in healthcare IT for a five-year period. It comes as no surprise therefore, that the UK healthcare IT market, powered by government initiatives, will reach $24.7 billion by the year 2025.

Get In-depth table of contents @ http://decresearch.com/toc/detail/healthcare-it-market

With the increasing prevalence of diseases and the subsequently rising demand for a sophisticated medical infrastructure, healthcare IT market contenders have been working to bring forth a slew of advancements in their service portfolio. For instance, McKesson Corporation has recently collaborated with technology leader Navigating Cancer to provide an enhanced Patient Relationship Management (PRM) platform for oncologists.

IT aided healthcare has come a long way since its inception. With massive changes in the technological landscape, many more innovations have been touted to disrupt the healthcare space. Powered by huge investments and the incorporation of advanced technologies in medical care management, healthcare IT market is expected to chart out a lucrative growth map in the forthcoming years.

Table Of Content

Chapter 1. Methodology

1.1. Methodology

1.2. Market definition

1.3. Forecast parameters

1.4. Data sources

1.4.1. Secondary

1.4.1.1. Paid sources

1.4.1.2. Unpaid sources

1.4.2. Primary

Chapter 2. Executive Summary

2.1. Healthcare information technology industry 3600 synopsis, 2014 - 2025

2.1.1. Business trends

2.1.2. Solution trends

2.1.3. End-use trends

2.1.4. Regional trends

Chapter 3. Healthcare Information Technology Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2014 - 2025

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Growing investment towards healthcare infrastructure development in Asia Pacific region

3.3.1.2. Growing adoption of artificial intelligence

3.3.1.3. High adoption of electronic health records in developed countries such as the U.S.

3.3.1.4. Favorable government initiatives

3.3.1.5. Increasing demand for cost-saving in healthcare delivery

3.3.2. Industry pitfalls & challenges

3.3.2.1. High cost associated with implementation and maintenance

3.3.2.2. Security and privacy concerns

3.4. Growth potential analysis

3.4.1. By solution

3.4.2. By end-use

3.5. Regulatory landscape

3.5.1. U.S.

3.5.2. Europe

3.5.3. China

3.6. Technology landscape

3.7. Porter's analysis

3.8. Competitive landscape, 2017

3.8.1. Strategy dashboard

3.9. PESTEL analysis

Read the original:
Healthcare IT Market trends research and projections - GroundAlerts.com

Recommendation and review posted by Alexandra Lee Anderson

Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 – Primo…

The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Healthcare Nanotechnology (Nanomedicine) Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Healthcare Nanotechnology (Nanomedicine) Market during the forecast period 2015 2021.

As per the findings of the presented study, the Healthcare Nanotechnology (Nanomedicine) Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Healthcare Nanotechnology (Nanomedicine) in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/6370

The report segregates the Healthcare Nanotechnology (Nanomedicine) Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Healthcare Nanotechnology (Nanomedicine) Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Healthcare Nanotechnology (Nanomedicine) Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Healthcare Nanotechnology (Nanomedicine) Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/6370

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

The rest is here:
Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 - Primo...

Recommendation and review posted by Alexandra Lee Anderson

What are the Upcoming Trends of Nanotechnology in Medicine? – Medical Tech Outlook

Nanotechnology is a rapidly expanding area of research with massive potential in many sectors ranging from healthcare to construction, and electronics.

FREMONT, CA: In the field of medicine, nanotechnology has revolutionized drug delivery, gene therapy, diagnostics, and various other areas of research, development and clinical application. Nanotechnology is a leading technology in medicine, bettering the potential of nanotechnology to target specific cells or tissues is a popular area of interest for the companies producing nanomedicines. Numerous registered clinical trials are in progress and involve nanotechnology; many of these studies are related to oncology and other therapy areas such as autoimmune diseases, anti-fungal agents and rare diseases. Playing a significant role in the transformation of medicine, identifying the trends in nanotechnology industry is essential.

Target Specification

The area of medicinal research involves attaching nanoparticles into drugs or liposomes to enhance specific localization. Different cell types have remarkable properties, and nanotechnology can be used to recognize cells of interest. This method enables associated drugs and therapeutics to reach diseased tissue while bypassing healthy cells.

Controlled Drug Release

The capability to control the discharge of a drug or therapeutic compound from its associated nanotechnology is benefitting a lot of interest from the industry. This triggered release can be gained from inside the body or from outside the body. The internal system consists of changes in the ecosystem of tumours in comparison with the surrounding tissues, while external stimuli comprise temperature change, ultrasound, or light. At present, the research efforts are dedicated to trying to understand how to release diagnostic molecules and drugs from liposomes with heat, and microbubbles using ultrasound.

Understanding Varied Patient Populations

Generally, there is a need for a better understanding of what makes patients distinctive from each other in terms of lack of ubiquitous drug efficacy. This raises a question, why nanotechnologies are not always able to improve the therapeutic output of drugs for an individual patient. Understanding the behaviour of nanomedicines when encountering different physiological characteristics of the patients and their disease states is significant.

Production of Nanomedicine

When compared to standard drug compounds, synthesizing and producing nanomedicine is primarily believed to be more complicated. In a few cases, this can limit the potential of drug manufacturers or pharmaceutical companies to deliver large quantities of nanomedicines. Not addressing the issues related to production may make the companies less interested in investing resources in this industry.

More:
What are the Upcoming Trends of Nanotechnology in Medicine? - Medical Tech Outlook

Recommendation and review posted by Alexandra Lee Anderson

A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN – Dove Medical Press

Yaser H Gholami, 1 4 Lee Josephson, 3 Eman A Akam, 5 Peter Caravan, 5 Moses Q Wilks, 3 Xiang-Zuo Pan, 3, 6 Richard Maschmeyer, 1 Aleksandra Kolnick, 3, 7 Georges El Fakhri, 3 Marc D Normandin, 3 Zdenka Kuncic, 1, 4, 8Hushan Yuan 3

1The University of Sydney, Faculty of Science, School of Physics, Sydney, NSW, Australia; 2Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Northern Sydney Local Health District, Sydney, Australia; 3Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 4Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia; 5The Institute for Innovation in Imaging and the A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States; 6Bouve College of Health Sciences, CaNCURE Program, Northeastern University, Boston, MA, USA; 7Internal Medicine Residency Program, Lahey Hospital and Medical Center, Burlington, MA, USA; 8The University of Sydney Nano Institute, Sydney, NSW, Australia

Correspondence: Hushan YuanGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 13 th Street, Charlestown, MA 02129, USATel +1 617-643-1963Email hyuan@mgh.harvard.edu

Purpose: Using our chelate-free, heat-induced radiolabeling (HIR) method, we show that a wide range of metals, including those with radioactive isotopologues used for diagnostic imaging and radionuclide therapy, bind to the Feraheme (FH) nanoparticle (NP), a drug approved for the treatment of iron anemia.Material and methods: FH NPs were heated (120C) with nonradioactive metals, the resulting metal-FH NPs were characterized by inductively coupled plasma mass spectrometry (ICP-MS), dynamic light scattering (DLS), and r 1 and r 2 relaxivities obtained by nuclear magnetic relaxation spectrometry (NMRS). In addition, the HIR method was performed with [ 90Y]Y 3+, [ 177Lu]Lu 3+, and [ 64Cu]Cu 2+, the latter with an HIR technique optimized for this isotope. Optimization included modifying reaction time, temperature, and vortex technique. Radiochemical yield (RCY) and purity (RCP) were measured using size exclusion chromatography (SEC) and thin-layer chromatography (TLC).Results: With ICP-MS, metals incorporated into FH at high efficiency were bismuth, indium, yttrium, lutetium, samarium, terbium and europium (> 75% @ 120 oC). Incorporation occurred with a small (less than 20%) but statistically significant increases in size and the r 2 relaxivity. An improved HIR technique (faster heating rate and improved vortexing) was developed specifically for copper and used with the HIR technique and [ 64Cu]Cu 2+. Using SEC and TLC analyses with [ 90Y]Y 3+, [ 177Lu]Lu 3+ and [ 64Cu]Cu 2+, RCYs were greater than 85% and RCPs were greater than 95% in all cases.Conclusion: The chelate-free HIR technique for binding metals to FH NPs has been extended to a range of metals with radioisotopes used in therapeutic and diagnostic applications. Cations with f-orbital electrons, more empty d-orbitals, larger radii, and higher positive charges achieved higher values of RCY and RCP in the HIR reaction. The ability to use a simple heating step to bind a wide range of metals to the FH NP, a widely available approved drug, may allow this NP to become a platform for obtaining radiolabeled nanoparticles in many settings.

Keywords: nanomedicine, radiolabeling, radionuclide therapy, HIR, Feraheme

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press

Recommendation and review posted by Alexandra Lee Anderson

What is the Role of Nanomedicine in Treating Melanoma? – Medical Tech Outlook

Nanomedicine involves smaller particles, yet their capabilities are tremendous, playing a more significant part in the diagnosis and treatment of cancer.

Fremont, CA: Nanomedicine uses particles and technology that is one-billionth of a meter in medicine for diagnosis and treatment of disease. Irrespective of their smaller size, these nanoparticles play a significant role in the medical field. According to cancer.net, nearly 96,480 cases of invasive melanoma of the skin will be diagnosed in 2019 in the US. Even though it is not the most common type of skin cancer, an estimation of 7,230 deaths will occur this year. In recent research, nanomedicine has been employed to help with improving detection, prevention and treatment of a severe form of skin cancer, melanoma.

The disease begins in the melanocytes, which are the cells responsible for the synthesis of a dark pigment called melanin. And when the skin is exposed to the sun for a long time, melanocytes start producing more pigment as a protective response causing the skin to darken more. When these cells grow out of control, it can result in melanoma.

Tel Aviv researchers have developed a nano-vaccine for melanoma. The vaccine was tested in mice, and it turned out to be useful as it prevents the development of melanoma. It also treats both primary tumors and disease that has spread throughout the body. It was observed by administering with immunotherapy that activates the immune system to fight against the foreign cells. Meanwhile, these cells learn to identify the melanoma cells and will start attacking cells of this specific cancer.

The researchers also examined the vaccine in different conditions. They injected the vaccine into healthy mice and then placed the melanoma cells in the mice where the vaccine halted the development of the disease. In another scenario, the vaccine and immunotherapy together were used to treat the mice already infected by melanoma. Here a significant delay in the progression of the disease was observed. Also, peptides which are the short amino acid chains used in the vaccine were present in the samples of melanoma tissue from different sites in the mice's body other than the one where melanoma had been injected initially. This proves that the vaccine is also suitable for patients affected severely for whom melanoma has spread beyond the primary site.

Read more from the original source:
What is the Role of Nanomedicine in Treating Melanoma? - Medical Tech Outlook

Recommendation and review posted by Alexandra Lee Anderson


Page 11234..1020..»